252 related articles for article (PubMed ID: 22986737)
21. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.
Bajetta E; Catena L; Fazio N; Pusceddu S; Biondani P; Blanco G; Ricci S; Aieta M; Pucci F; Valente M; Bianco N; Mauri CM; Spada F
Cancer; 2014 Aug; 120(16):2457-63. PubMed ID: 24752410
[TBL] [Abstract][Full Text] [Related]
22. Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors.
Costello BA; Borad MJ; Qi Y; Kim GP; Northfelt DW; Erlichman C; Alberts SR
Invest New Drugs; 2014 Aug; 32(4):710-6. PubMed ID: 24740268
[TBL] [Abstract][Full Text] [Related]
23. 18F-FDG and 18F-FLT-PET imaging for monitoring everolimus effect on tumor-growth in neuroendocrine tumors: studies in human tumor xenografts in mice.
Johnbeck CB; Munk Jensen M; Haagen Nielsen C; Fisker Hag AM; Knigge U; Kjaer A
PLoS One; 2014; 9(3):e91387. PubMed ID: 24626055
[TBL] [Abstract][Full Text] [Related]
24. [Management of metabolic disorders induced by everolimus in patients with differentiated neuroendocrine tumors: expert proposals].
Lombard-Bohas C; Cariou B; Vergès B; Coriat R; N'guyen T; François E; Hammel P; Niccoli P; Hentic O
Bull Cancer; 2014 Feb; 101(2):175-83. PubMed ID: 24557872
[TBL] [Abstract][Full Text] [Related]
25. Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison.
Signorovitch J; Swallow E; Kantor E; Wang X; Klimovsky J; Haas T; Devine B; Metrakos P
Exp Hematol Oncol; 2013 Dec; 2(1):32. PubMed ID: 24314093
[TBL] [Abstract][Full Text] [Related]
26. Dual inhibition of PI3K and mTOR signaling pathways decreases human pancreatic neuroendocrine tumor metastatic progression.
Djukom C; Porro LJ; Mrazek A; Townsend CM; Hellmich MR; Chao C
Pancreas; 2014 Jan; 43(1):88-92. PubMed ID: 24263107
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.
Kamp K; Gumz B; Feelders RA; Kwekkeboom DJ; Kaltsas G; Costa FP; de Herder WW
Endocr Relat Cancer; 2013 Dec; 20(6):825-31. PubMed ID: 24036133
[TBL] [Abstract][Full Text] [Related]
28. Everolimus in the treatment of patients with advanced pancreatic neuroendocrine tumors: latest findings and interpretations.
Liu E; Marincola P; Oberg K
Therap Adv Gastroenterol; 2013 Sep; 6(5):412-9. PubMed ID: 24003341
[TBL] [Abstract][Full Text] [Related]
29. Drug interactions and the pharmacist: focus on everolimus.
Grabowsky JA
Ann Pharmacother; 2013; 47(7-8):1055-63. PubMed ID: 23757385
[TBL] [Abstract][Full Text] [Related]
30. A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.
Chan JA; Blaszkowsky L; Stuart K; Zhu AX; Allen J; Wadlow R; Ryan DP; Meyerhardt J; Gonzalez M; Regan E; Zheng H; Kulke MH
Cancer; 2013 Sep; 119(17):3212-8. PubMed ID: 23733618
[TBL] [Abstract][Full Text] [Related]
31. Practical management of everolimus-related toxicities in patients with advanced solid tumors.
Grünwald V; Weikert S; Pavel ME; Hörsch D; Lüftner D; Janni W; Geberth M; Weber MM
Onkologie; 2013; 36(5):295-302. PubMed ID: 23689226
[TBL] [Abstract][Full Text] [Related]
32. Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors.
Chan JA; Mayer RJ; Jackson N; Malinowski P; Regan E; Kulke MH
Cancer Chemother Pharmacol; 2013 May; 71(5):1241-6. PubMed ID: 23475104
[TBL] [Abstract][Full Text] [Related]
33. Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas.
Bollard J; Couderc C; Blanc M; Poncet G; Lepinasse F; Hervieu V; Gouysse G; Ferraro-Peyret C; Benslama N; Walter T; Scoazec JY; Roche C
Neuroendocrinology; 2013; 97(4):331-40. PubMed ID: 23343749
[TBL] [Abstract][Full Text] [Related]
34. Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study.
Castellano D; Bajetta E; Panneerselvam A; Saletan S; Kocha W; O'Dorisio T; Anthony LB; Hobday T;
Oncologist; 2013; 18(1):46-53. PubMed ID: 23263288
[TBL] [Abstract][Full Text] [Related]
35. Rash to the mTOR inhibitor everolimus: systematic review and meta-analysis.
Ramirez-Fort MK; Case EC; Rosen AC; Cerci FB; Wu S; Lacouture ME
Am J Clin Oncol; 2014 Jun; 37(3):266-71. PubMed ID: 23241507
[TBL] [Abstract][Full Text] [Related]
36. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
Fazio N; Granberg D; Grossman A; Saletan S; Klimovsky J; Panneerselvam A; Wolin EM
Chest; 2013 Apr; 143(4):955-962. PubMed ID: 23187897
[TBL] [Abstract][Full Text] [Related]
37. mTOR inhibitor RAD001 promotes metastasis in a rat model of pancreatic neuroendocrine cancer.
Pool SE; Bison S; Koelewijn SJ; van der Graaf LM; Melis M; Krenning EP; de Jong M
Cancer Res; 2013 Jan; 73(1):12-8. PubMed ID: 23149918
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis.
Capdevila J; Sevilla I; Alonso V; Antón Aparicio L; Jiménez Fonseca P; Grande E; Reina JJ; Manzano JL; Alonso Lájara JD; Barriuso J; Castellano D; Medina J; López C; Segura Á; Carrera S; Crespo G; Fuster J; Munarriz J; García Alfonso P
BMC Cancer; 2015 Jul; 15():495. PubMed ID: 26138480
[TBL] [Abstract][Full Text] [Related]
39. Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer.
Matsumoto M; Seike M; Noro R; Soeno C; Sugano T; Takeuchi S; Miyanaga A; Kitamura K; Kubota K; Gemma A
BMC Cancer; 2015 Apr; 15():241. PubMed ID: 25884680
[TBL] [Abstract][Full Text] [Related]
40. Current clinical trials of targeted agents for well-differentiated neuroendocrine tumors.
Raj N; Reidy-Lagunes D
Pancreas; 2014 Nov; 43(8):1185-9. PubMed ID: 25333401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]